BCLI - Brainstorm Cell Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.10
-0.04 (-0.97%)
As of 11:01AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.14
Open4.18
Bid4.11 x 100
Ask4.15 x 200
Day's Range4.10 - 4.18
52 Week Range2.06 - 5.18
Volume16,445
Avg. Volume87,483
Market Cap77.26M
Beta2.29
PE Ratio (TTM)-15.19
EPS (TTM)-0.27
Earnings DateNov 13, 2017 - Nov 17, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Trade prices are not sourced from all markets
  • ACCESSWIRE4 hours ago

    Corporate News Blog - Novan Acquires Intellectual Property Rights for Treating Viral Malignancies with Nitric Oxide

    Research Desk Line-up: Brainstorm Cell Therapeutics Post Earnings Coverage LONDON, UK / ACCESSWIRE / October 20, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the ...

  • ACCESSWIREyesterday

    Featured Company News - Syndax Pharma Signs Worldwide License Agreement for Allergan's Portfolio of Menin-MLL Inhibitors

    Research Desk Line-up: Brainstorm Cell Therapeutics Post Earnings Coverage LONDON, UK / ACCESSWIRE / October 19, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines ...

  • Zacks Small Cap Research3 days ago

    BCLI: Initiates Phase 3 Clinical Trial of NurOwn® in ALS

    On October 16, 2017, BrainStorm (BCLI) announced that the first patients have been enrolled in the Phase 3 clinical trial of NurOwn® (NCT03280056) for the treatment of amyotrophic lateral sclerosis (ALS). The Phase 3 clinical trial is a randomized, double blind, placebo controlled, multi-dose trial that will take place at six leading ALS centers in the U.S. We anticipate approximately 200 patients being enrolled in the trial randomized 1:1 to NurOwn® or placebo. The company is focusing the trial on faster-progressing ALS patients since these patients demonstrated superior outcomes in the Phase 2 trial of NurOwn®.

  • PR Newswire3 days ago

    BrainStorm Announces Third Quarter 2017 Financial Results

    Conference Call with Management to Discuss Recent Corporate Progress at 8:30am Eastern Time Today HACKENSACK, N.J. and PETACH TIKVAH, Israel , Oct. 17, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics ...

  • ACCESSWIRE3 days ago

    Investor Network: Brainstorm Cell Therapeutics Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / October 17, 2017 / Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI ) will be discussing their earnings results in their Q3 Earnings Call to be held October 17, 2017 at 8:30:00 ...

  • PR Newswire4 days ago

    BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn® in ALS

    HACKENSACK, N.J. and PETACH TIKVA, Israel, Oct. 16, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI) today announced that the first patients have been enrolled in the Phase 3 clinical trial of NurOwn® for the treatment of amyotrophic lateral sclerosis (ALS) at the Massachusetts General Hospital and UC Irvine Medical Center in California. The patient population will be optimized to include the pre-specified subgroups who demonstrated superior outcomes in the NurOwn® Phase 2 ALS clinical trial. Top-line data are expected in 2019.

  • Reuters4 days ago

    BrainStorm enrolls first patients in advanced ALS stem cell trial

    BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California. The Phase 3 clinical trial is expected to include about 200 patients and will be conducted at six ALS clinical sites in the United States, Israel-based BrainStorm said on Monday. The company is developing a treatment made from adult stem cells for patients with ALS, a neuro-degenerative disease.

  • PR Newswire17 days ago

    Brainstorm to Announce Third Quarter Financial Results And Provide Corporate Updates on Tuesday, October 17

    Conference Call and Live Webcast at 8:30am Eastern Time HACKENSACK, N.J. and PETACH TIKVAH, Israel , Oct. 3, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of ...

  • PR Newswire23 days ago

    BrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by SeeThruEquity and RHK Capital

    HACKENSACK, N.J. and PETACH TIKVAH, Israel, Sept. 27, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases announced today that it will be presenting at the 2017 Disruptive Growth Company Showcase NYC at 4 PM EDT/ 1 PM PDT on September 27, 2017 at the Grand Hyatt 109 E 42nd St.  Ralph Z. Kern, MD MHSc, Chief Operating Officer and Chief Medical Officer will be presenting, as well as meeting with investors. Each company will be provided with a 30-minute time slot to present to an audience of investors and industry professionals and company management will also be available for one-on-one meetings with institutional investors. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased.

  • Zacks Small Cap Research2 months ago

    BCLI: Phase 3 Trial of NurOwn® to Initiate Soon

    On August 14 2017, BrainStorm (BCLI) announced financial results for the second quarter of 2017. As expected, the company did not report any revenue. The increase was due to an increase in payroll and stock-based compensation partially offset by a decrease in costs related to the U.S. clinical trial.

  • ACCESSWIRE2 months ago

    Investor Network: Brainstorm Cell Therapeutics Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 16, 2017 / Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI ) will be discussing their earnings results in their Q2 Earnings Call to be held August 16, 2017 at 8:30 AM ...

  • PR Newswire2 months ago

    BrainStorm Announces Second Quarter 2017 Financial Results

    Conference Call with Management to Discuss Recent Progress Wednesday, August 16, 2017 @ 8:30am Eastern Time HACKENSACK, N.J. and PETACH TIKVAH, Israel , Aug. 15, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics ...

  • PR Newswire2 months ago

    BrainStorm Announces Second Quarter 2017 Financial Results

    Conference Call with Management to Discuss Recent Progress Wednesday, August 16, 2017 @ 8:30am Eastern Time HACKENSACK, N.J. and PETACH TIKVAH, Israel , Aug. 14, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics ...

  • PR Newswire2 months ago

    Brainstorm to Host Second-Quarter 2017 Earnings Teleconference and Provide Important Corporate Updates, on Wednesday, August 16

    HACKENSACK, N.J. and PETACH TIKVAH, Israel , Aug. 10, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases ...

  • PR Newswire2 months ago

    BrainStorm Supports Commitment to ALS Patient Community with Appointment of a Vice President of Patient Advocacy and Government Affairs

    HACKENSACK, N.J. and PETACH TIKVAH, Israel, Aug. 7, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today the appointment of Mary Kay Turner to the position of Vice President of Patient Advocacy and Government Affairs, effective August 7, 2017. Ms. Turner joins BrainStorm from Mitsubishi Tanabe Pharma America, where she was Head of Patient Advocacy and Communications supporting the commercialization of edaravone (Radicava™) for amyotrophic lateral sclerosis (ALS).  Her prior industry experience includes senior sales leadership roles and she was Head of State Government Affairs and Advocacy for Bristol-Myers Squibb Company.

  • PR Newswire3 months ago

    BrainStorm Announces Agreement with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn® in ALS

    HACKENSACK, N.J. and PETACH TIKVA, Israel, July 25, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has signed a definitive agreement with the University of California Irvine Medical Center (UCI) to enroll patients in the planned Phase 3 clinical trial of NurOwn® in amyotrophic lateral sclerosis (ALS), pending FDA and Institutional Review Board approvals. Dr. Namita Goyal has agreed to participate as Principal Investigator at UCI.

  • Zacks Small Cap Research3 months ago

    BCLI: Receives $16 Million Grant From CIRM to Fund Phase 3 Trial in ALS

    On July 21, 2017, BrainStorm (BCLI) announced that the company has received a $16 million grant from the California Institute for Regenerative Medicine (CIRM) to help fund the company’s upcoming Phase 3 clinical trial of NurOwn® in patients with amyotrophic lateral sclerosis (ALS).  CIRM was established in 2004 through Proposition 71: the California Stem Cell Research and Cures Initiative. While CIRM initially concerned itself with supporting scientists who were just entering the stem cell field, the organization has recently launched CIRM 2.0, which aims to make funding available sooner for projects that are likely to bring stem cell therapies to patients with unmet medical needs (e.g., late stage clinical trials).

  • PR Newswire3 months ago

    Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn® in ALS

    The grant from CIRM is a significant endorsement of the potential for Brainstorm's novel approach to treat ALS using adult stem cells. CIRM is the World's Largest Institution Dedicated to Cell Therapies. "We are honored to be awarded this CIRM grant, and appreciate the support of CIRM in the development of NurOwn," said Chaim Lebovits, President and CEO of Brainstorm.

  • PR Newswire3 months ago

    BrainStorm Announces Agreements with Mass. General Hospital and California Pacific Medical Center to Participate in Phase 3 Trial of NurOwn® in ALS

    HACKENSACK, N.J. and PETACH TIKVA, Israel, July 18, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has signed definitive agreements with Massachusetts General Hospital and California Pacific Medical Center (CPMC) to enroll patients in the planned Phase 3 clinical trial of NurOwn® in amyotrophic lateral sclerosis (ALS), pending FDA and Institutional Review Board approvals.

  • PR Newswire4 months ago

    Worldwide Clinical Trials Selected by BrainStorm as CRO for Phase 3 NurOwn Trial in ALS

    HACKENSACK, N.J. and PETACH TIKVAH, Israel , July 3, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, ...

  • PR Newswire4 months ago

    BrainStorm to Provide Corporate Update at the BIO International Convention

    HACKENSACK, N.J. and PETACH TIKVAH, Israel , June 14, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, ...

  • Zacks Small Cap Research4 months ago

    BCLI: Phase 3 Trial of NurOwn® in Final Stages of Preparation

    On December 19, 2016, BrainStorm (BCLI) announced that the company had a successful End-of-Phase 2 meeting with the U.S. FDA in which the FDA accepted the key elements of the Phase 3 program for NurOwn® in amyotrophic lateral sclerosis (ALS). The planned Phase 3 clinical trial will be a randomized, double blind, placebo controlled, multi-dose trial that will take place at six leading ALS centers in both the U.S. and Israel. The company is focusing the trial on faster-progressing ALS patients since these patients demonstrated superior outcomes in the Phase 2 trial of NurOwn®.

  • PR Newswire4 months ago

    BrainStorm Awarded $2.1 Million Non-Dilutive Grant for 2017 by the Israel Innovation Authority

    HACKENSACK, N.J. and PETACH TIKVAH, Israel, June 13, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded a new grant of approximately $2.1 million by the Israel Innovation Authority (IIA) (Formerly called "the Office of the Chief Scientist (OCS)". The funds will support the development of NurOwn®, BrainStorm's innovative mesenchymal stem cell-based platform for the treatment of neurodegenerative diseases.

  • PR Newswire5 months ago

    BrainStorm to Present at Cell & Gene Exchange Conference in Washington DC

    HACKENSACK, N.J. and PETACH TIKVAH, Israel, May 22, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, ...

  • PR Newswire5 months ago

    BrainStorm Initiated Technology Transfer to City of Hope for U.S. Production of NurOwn® for Phase 3 ALS Study

    HACKENSACK, N.J., PETACH TIKVA, Israel and DUARTE, Calif., May 16, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has begun training the cell manufacturing team at City of Hope's Center for Biomedicine and Genetics to produce clinical supplies of NurOwn® adult stem cells for the company's randomized, double-blind, multi-dose Phase 3 clinical study in patients with Amyotrophic Lateral Sclerosis (ALS).  City of Hope will be the clinical supplier for all U.S. medical centers participating in the Phase 3 trial. "City of Hope is one of the world's pre-eminent cell product manufacturing centers," said Chaim Lebovits, President and CEO of BrainStorm.